Boehringer Ingelheim and Gubra send obesity drug candidate to clinical trial

Years of collaboration among Gubra and Boehringer Ingelheim have now entered a new phase after the partnership's first potential drug has entered clinical trials on human subjects.
Photo: Muusfoto / Gubra / PR
Photo: Muusfoto / Gubra / PR

The first possible medicament from Danish biotechnology and contract research organization Gubra's partnership with Germany's Boehringer Ingelheim has now entered its first clinical trial phase, the latter informs in a press statement.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading